For establishing a statistical risk assessment model as a future staging system, the AJCC presents the recommended pretreatment variables in the Cancer Staging Manual,1 such as tumor location, tumor size, location of clinical positive nodes, sites of distant metastasis, serum CEA, and serum CA19‐9, in parallel with traditional factors including depth of invasion (cT) and number of clinically malignant nodes (cN). This evidence concerns the gene CEACAM5 and neoplasm.